Actavis Rating Increased to Buy at Goldman Sachs (ACT)
Actavis (NYSE:ACT) was upgraded by equities researchers at Goldman Sachs to a “buy” rating in a research report issued on Wednesday, Analyst RN reports.
Actavis (NYSE:ACT) opened at 201.47 on Wednesday. Actavis has a 52-week low of $82.02 and a 52-week high of $193.21. The stock has a 50-day moving average of $180.9 and a 200-day moving average of $155.8. The company’s market cap is $35.056 billion.
Several other analysts have also recently commented on the stock. Analysts at Zacks upgraded shares of Actavis from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 4th. They now have a $224.00 price target on the stock. Separately, analysts at Morgan Stanley raised their price target on shares of Actavis from $182.00 to $205.00 in a research note on Monday, February 3rd. Finally, analysts at RBC Capital raised their price target on shares of Actavis from $202.00 to $222.00 in a research note on Monday, February 3rd. They now have an “outperform” rating on the stock. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Actavis currently has an average rating of “Buy” and a consensus price target of $182.50.
Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.